Breast cancer doc, educator, researcher. Passionate about quality of cancer care. All tweets are my own.
New Haven, CT
Joined April 2019
- Tweets44
- Following225
- Followers203
- Likes69
Such a privilege to work in a fantastic cancer center with amazing colleagues and patients.
Sarah Schellhorn Mougalian, MD @SMougalian, focuses her care on patients with #breastcancer, working closely with a multidisciplinary team to address every patient's goals & treatment options. #bcsm
Read more from Dr. Mougalian bit.ly/3uwcoNq @SmilowCancer @YaleMed @YNHH
Sarah Schellhorn (Mougalian) retweeted
Amazing work on outcomes and race in early-stage TNBC receiving durvalumab! #ASCO22 #breastcancer #equity @JuliaFoldiMD @YaleHemOnc @YaleCancer @SmilowCancer
Sarah Schellhorn (Mougalian) retweeted
.@NorinAnsariMD will present new data highlighting differences in mutations between younger and older patients with #breastcancer in a poster session this morning #ASCO22 in Hall A. #bcsm @maryam_lustberg @MariyaRozenblit @SmilowCancer @YaleMed bit.ly/3MlRaI2
Outstanding piece by my amazing colleague, Dr. Tara Sanft, on the emotions we face as physicians caring for patients at the end of life. @tarasanftmd @maryam_lustberg
academic.oup.com/oncolo/adva…
This guy: the epitome of mentorship. I’m honored to work with him.
Huge congratulations to our incredible director, @cpgYALE, on receiving the Yale Cancer Center Award for Mentorship Excellence! 🎉 Such a well-deserved recognition for a generous and talented mentor and collaborator! @YaleCancer @YaleMed @NCSP_Yale
Sarah Schellhorn (Mougalian) retweeted
At this year’s #SABCS, Dr. Mariya Rozenblit presented new research observing longer survival times for #breastcancer patients using everolimus exemestane as a third line treatment following prior CDK4/6 inhibitor therapy. @SmilowCancer @YaleMed @YNHH @SMougalian @SABCSSanAntonio – at New Haven, CT
Fantastic reminder! Using this today in a letter for an accomplished, already successful mentee.
This Post is from an account that no longer exists. Learn more
Thanks @SUMOncol for the invitation to present in beautiful Park City, UT! Great to spend time chatting with @marklewismd @ClarkeLow @YaleCancer
.@SMougalian @YaleCancer speaks to @SUMOncology on the explosion of new FDA-approved therapies in breast cancer in the last several years cc: @MVanMeterMD #bcsm
Sequencing of treatment remains a major area of investigation
Sarah Schellhorn (Mougalian) retweeted
Take 2 Aspirin? How about take 2 seconds to look at data showing the impact of decades of reliance on biomedical model: persistent inequity in #cancer (& other) outcomes. bit.ly/2kK4XBw Only redeeming feature of this @WSJ piece: author is FORMER dean of curriculum.
Sarah Schellhorn (Mougalian) retweeted
Great to see the full range of @YaleCOPPER work from screening to end of care at #ASCOQLTY19. Congrats to @NataliaKunst, Amy Davidoff
Sarah Schellhorn (Mougalian) retweeted
New findings in #breastcancer research journal led by .@SMougalian and Dr. Bridget Killela finds women receiving neoadjuvant #endocrinetherapy had simliar rates of breast conservation surgery compared to neoadjuvant #chemotherapy. @YaleMed @YNHH ncbi.nlm.nih.gov/pubmed/3140…
Thank you @YaleCancer @DrRoyHerbstYale for the opportunity. Great to meet and reconnect with local and not-so-local oncologists!
.@SMougalian leads a discussion of #breastcancer cases and treatment pathways at #YaleASCO19 with highlights of practice changing data from #ASCO19 @ASCO @YaleMed @YNHH
Thrilled to be acknowledged by our heme/onc fellows! It is indeed an honor and a privilege, and congratulations to all 2019 graduates!
Congratulations to @SMougalian of Yale Medical Oncology @YaleCancer winner of the 2019 teaching award as chosen by our graduating fellows @YNHH @YaleMedicine @YaleMed. Pictured here with fellowship director Dr. Jill Lacy.
Sarah Schellhorn (Mougalian) retweeted
From @nytopinion: Corporate medicine has milked just about all the “efficiency” it can from the health care system. But one resource seems endless — and free: the professionalism of doctors and nurses, who are overworked and burning out. nyti.ms/2QUMZb6
Sarah Schellhorn (Mougalian) retweeted
Eloquent review of low dose tam and PRS in breast cancer prevention by Dr Erin Hoffstatter @YaleCancer. We need better ABC’s - Agents, Biomarkers, Cohort Selection. 👈 Really an outstanding presentation and exciting to see some movement in breast cancer prevention! #ASC019
Sarah Schellhorn (Mougalian) retweeted
Colleagues: could we consider referring to “patient deaths” instead of “grade 5 events?” Let’s keep it patient-centered. #ASCO19
Sarah Schellhorn (Mougalian) retweeted
Nonadherence to aromatase inhibitors is common. A simple text messaging intervention study was negative.
—@DrDawnHershman #ASCO19 #bcsm #SWOGOnc
Sarah Schellhorn (Mougalian) retweeted
Getting ready to discuss LBA1 @ASCO plenary! I'm live tweeting thx to @DukeGUCancer. Follow to see why this study is worthy of the plenary stage:
1) It is practice changing
2) It’s a proof-of-concept that health policy can improve cancer quality and reduce disparities
#ASCO19
